Patel Chem Specialties Limited is a trusted leader in the manufacturing of high-quality pharmaceutical excipients - raw material for drug formulation. With decades of experience, they specialize in producing a wide range of excipients, including Sodium Carboxy Methyl Cellulose (Sodium CMC), Sodium Starch Glycolate (SSG), Croscarmellose sodium (CCS), Calcium CMC, Magnesium stearate andpregelatinised starch and also producing key API intermediate Sodium Monochloroacetate.
Patel Chem Specialities, an Book Built Issue, amounting to ₹ 58.8 Crores, consistingentirelyan Fresh Issue of 70.00 Lakh Shares. The subscription period for the Patel Chem Specialities IPO opens on July 25, 2025, and closes on July 29, 2025. The allotment is expected to be finalized on or about Wednesday, July 30, 2025, and the shares will be listed on the BSE SME with a tentative listing date set on or about Friday, August 01, 2025.
The Share Price Band of Patel Chem Specialities IPO is set at ₹ 82 to₹ 84 per equity share. The Market Capitalisation of the Patel Chem Specialities at IPO price of ₹ 84 per equity share will be ₹ 208.90 Crores. The lot size of the IPO is 1,600 shares. Individual investors are required to invest a minimum of 2 lots (3,200 shares), amounting to ₹ 2,68,800.
CUMULATIVE CAPITAL PRIVATE LIMITED and UNISTONE CAPITAL PRIVATE LIMITEDare the book running lead manager of the Patel Chem Specialities, while MUFG Intime India Private Limitedis the registrar for the issue. Globalworth Securities Limitedis the Market Maker for Patel Chem Specialities IPO.
Patel Chem Specialities LimitedIPO GMP Today
The Grey Market Premium of Patel Chem Specialities IPO is expected to be ₹ 11 based on the financial performance of the company. No real trading is done on the basis of Grey Market Premium that's why no real discovery of price can be done before the listing of shares on the stock exchange. The Grey Market Premium totally depends upon the Demand and Supply of the shares of the company in unorganized manner which is not recommended. The Grey Market Premium is mentioned for educational and informational purposes only.
Patel Chem Specialities LimitedIPO Live Subscription Status Today: Real-Time Update
As of 11:30 AM on 25 July, 2025, the Patel Chem Specialities Limited IPO live subscription status shows that the IPO subscribed 0.67 times on its First Day of subscription period. Check the Patel Chem Specialities IPO Live Subscription Status Today at BSE.
Patel Chem Specialities IPO Anchor Investors Report Patel Chem Specialities has raised ₹ 16.69 Crores from Anchor Investors at a price of ₹ 84 per shares in consultation of the Book Running Lead Managers. The company allocated 19,87,200 equity shares to the Anchor Investors. Check Full List of Patel Chem Specialities Anchor Investor List.
Note:- Equity Shares allotted to Anchor Investors (if any) are allotted from Qualified Institutional Buyers (QIBs) reservation portion. Note:- The Number of shares offered shown IPO subscription section table is calculated at the lower end of the price band and Number of shares calculated in IPO details table section is calculated at upper end of the price band in case of Book Building Issue, so there can be difference. This is because we assume shares will be issued by the company at upper band as Anchor Investors also subscribe at upper band and shares will be issued at lower band only if in case of undersubscription of IPO.
Note:- Market Maker portion (if any) are not shown separately in subscription table and included in NIIs reservation portion.
Patel Chem Specialities Limited IPO Allotment Date - Step by Step Guide to Check Allotment Status Online Patel Chem Specialities IPO allotment date is 30 July, 2025, Wednesday. Patel Chem Specialities IPO Allotment will be out on 30th July, 2025 and will be live on Registrar Website from the allotment date. Check Patel Chem Specialities IPO Allotment Status here. Here's how you can check the allotment status:
- Navigate to the IPO allotment status page.
- Select Patel Chem Specialities Limited IPO from the dropdown list of IPOs
- Enter your application number, PAN, or DP Client ID
- Submit the details to check your allotment status.
By following either of these methods, investors can quickly determine their allotment status and proceed accordingly with their investments.
Objectives of Patel Chem Specialities LimitedIPO
Patel Chem Specialities to utilise the Net Proceeds towards the following objects: 1. ₹ 4,314.78 Lakh is required for Funding capital expenditure requirement of the company towards; To Set up plant at Indrad, Mahesana for manufacturing Croscarmellose Sodium (“CCS”), Sodium Starch Glycolate (“SSG”) – Corn Starch Base & Potato Starch Base and Calcium Carboxymethylcellulose (CMC). 2. General corporate purposes
Patel Chem Specialities operates in the specialty chemicals sector with a focus on cellulose-based excipients used across pharmaceuticals, food & beverages, cosmetics, and industrial applications. These products serve critical roles as binders, disintegrants, thickeners, stabilizers, and gelling agents in tablets, food additives, personal care products, and industrial formulations.
The company manufactures and markets six key products:
Sodium Monochloro Acetate (SMCA) – Key raw material for various cellulose derivatives and drug APIs
Product applications span pharmaceuticals, oil drilling, food processing, cosmetics, and industrial manufacturing. With a global footprint in over 15 countries including the USA, Germany, UK, Japan, China, and Australia, the company adheres to international standards such as US-DMF, GMP, ISO 9001:2015.
Manufacturing units are located in Vatva (Ahmedabad) and Talod (Himmatnagar), operating under strict quality control protocols. The company has built a niche in high-quality cellulose-based excipients with a strong emphasis on innovation and compliance. As on March 31,2025, the comapny have the total strength of 136 employees on payroll basis. The Banker to the company is Bank of India Limited.
INDUSTRY ANALYSIS
Industry Overview: Specialty Cellulose Derivatives and Their Applications
Product Types and Applications
The company operates in a niche segment involving the manufacture of cellulose-based and starch-derived compounds that cater to a diverse range of industries. These include:
Carboxymethyl Cellulose Sodium (Sodium CMC):
A versatile white powder, Sodium CMC is widely used as a thickener, binder, gelling agent, suspending agent, and stabilizer. It finds applications across pharmaceuticals, food and beverages, cosmetics, and various industrial uses such as toothpaste, hand wash, oil well drilling, ceramics, paints, pencils, mining, agriculture, soaps and detergents, textiles, and paper manufacturing.
Microcrystalline Cellulose (MCC):
MCC is a purified, fine white, odorless powder derived from wood pulp. It serves as a texturizer, anti-caking agent, binder, bulking agent, and lubricant, with major applications in pharmaceuticals, nutraceuticals, food and beverages, and cosmetic industries.
Sodium Starch Glycolate (SSG):
A critical disintegrant in pharmaceutical and nutraceutical formulations, SSG enhances drug absorption by promoting rapid tablet breakup upon ingestion.
Croscarmellose Sodium and Carboxymethyl Cellulose Calcium (Calcium CMC):
Both serve as super-disintegrants in tablets, offering fast-swelling properties with low water solubility. They enable superior dissolution and faster therapeutic action in pharmaceutical and nutraceutical products.
Sodium Monochloro Acetate (SMCA):
A key intermediate chemical used in the production of Sodium CMC and SSG. SMCA also serves as a precursor in the manufacture of APIs such as Citrazin, modified starches, printing gums, and Betaine—a vital nutritional additive.
Pharmaceutical Industry in India: Current Landscape
India's pharmaceutical sector is globally recognized for its dominance in generic drugs and cost-effective vaccines. Ranked 3rd globally by volume and 14th by value, the industry contributes around 1.72% to India’s GDP.
Market Size & Growth:
Valued at USD 49.78 billion in FY23, the Indian pharmaceutical industry is projected to reach USD 65 billion by 2024 and USD 130 billion by 2030. Exports play a significant role, accounting for over US$ 27.9 billion in FY24.
Core Segments:
The industry comprises generics, OTC medicines, APIs/Bulk drugs, vaccines, biosimilars, biologics, and contract research & manufacturing services (CRAMS).
Government Support & R&D Push:
The government has amplified R&D spending through schemes such as PRIP and is setting up bulk drug parks, medical device parks, and nursing colleges. It has also encouraged partnerships with private research institutions and earmarked over ₹1,300 crore (US$ 156.5 million) for the pharma sector in FY25.
Global Export Reach:
Indian drugs are exported to over 200 countries, with the US, EU, and Japan being major markets. India is also the third-largest manufacturer of APIs globally, supplying over 500+ APIs and contributing 57% to WHO’s prequalified list.
Food & Beverage Industry in India
India's F&B sector is witnessing rapid expansion and innovation, supported by a growing consumer base and evolving consumption patterns.
Market Dynamics:
From US$ 30.12 billion in 2015, the sector was projected to reach US$ 142 billion by 2020, growing at a CAGR of 36.34%. Beverages alone contribute about $16 billion, with tea and coffee leading consumption.
Growth Drivers:
India's demographic dividend, rising disposable incomes, and increased urbanization are fueling demand. India is among the top producers of milk, pulses, rice, and vegetables—strengthening raw material supply for the sector.
Future Outlook:
India is poised to become the third-largest consumer economy by 2025. Traditional and modern retail coexist, and rising demand for packaged food and health-focused beverages presents opportunities for cellulose-based additives like MCC and Sodium CMC.
Cosmetics Industry in India
The Indian cosmetics industry is among the fastest-growing globally, expected to expand from USD 6.5 billion to USD 20 billion by 2025 at a CAGR of 25%.
Segments:
Includes skincare, haircare, oral care, color cosmetics, and fragrances.
Consumer Trends:
Rising income levels, beauty consciousness, and digital awareness—especially via social media—are driving consumption across metros and Tier 1/2 cities.
Herbal & Ayurvedic Shift:
Herbal cosmetics are gaining momentum, projected to grow at 15% CAGR. Many brands are capitalizing on the shift toward natural and Ayurvedic products.
Global Microcrystalline Cellulose (MCC) Market Overview
Pre-COVID Trends:
The global MCC market was projected to grow from USD 938 million in 2019 to USD 1,315 million by 2024, with a 7% CAGR, driven by growth in pharmaceuticals, processed food, and cosmetics.
Regional Insights:
North America holds the largest market share, followed by Europe and Asia-Pacific. The Indian MCC market was valued at USD 85 million in 2018 and projected to reach USD 115 million by 2022 at a 6.25% CAGR.
Post-COVID Recovery:
The MCC market faced temporary setbacks due to disruptions in the supply chain and reduced industrial output. However, with a projected V-shaped recovery, demand in core sectors like pharma, F&B, and personal care is expected to rebound, supporting long-term MCC growth.
Export-Import Trends (FY24)
Total Pharma Turnover: ₹4,17,345 crore (10% YoY growth)
Exports: ₹2,19,438.6 crore
Imports: ₹58,440.37 crore
India continues to be a net exporter of pharmaceutical goods and an essential player in global healthcare supply chains.
Conclusion: Industry Outlook
The specialty chemicals and cellulose derivative industry is positioned to benefit from the robust growth of India’s pharmaceutical, food & beverage, and cosmetics sectors. With increasing regulatory support, a shift toward health and hygiene-focused products, and rising global demand, the outlook for these product categories remains positive in the medium to long term.
BUSINESS STRENGTHS
1. Diverse Product Portfolio
Manufactures five key pharmaceutical excipients—SSG, CCS, Calcium CMC, Sodium CMC, and MCC—and one fine chemical, SMCA. Products are marketed domestically and exported to over 15 countries, with ongoing development of niche, application-specific solutions.
2. Experienced Leadership
Promoted by professionals with over 25 years of industry experience, including Managing Director Bhupesh Patel, a chemical engineer. The leadership team brings deep expertise in cellulose and starch derivatives, enabling strategic business growth.
3. Established Global Presence
Active in both direct and indirect exports, the company supplies products across North America, Europe, Asia, and Australia. International marketing efforts include trade participation and customer engagement across key regions.
4. Wide Customer Base
As of March 31, 2025, served over 350 customers spanning multiple industries and global markets, including dealers and agents.
5. Innovation & R&D Capabilities
Operates an in-house R&D facility at Vatva equipped with advanced analytical labs focused on cost-efficient process development and customized product innovations. Regular customer engagement drives solution-oriented development.
6. Strategically Located Facilities
Manufacturing units in Vatva (Ahmedabad) and Talod (Himmatnagar) enable efficient domestic and global distribution. A new facility in Indrad (Mehsana) is planned to meet growing demand in key product lines.
7. Strong Supply Chain Network
Sources key raw materials like cellulose ether and wood pulp sheets from reputed suppliers in China, Indonesia, Canada, and Sweden. Maintains long-standing relationships to ensure timely, high-quality material procurement.
8. Robust Quality Assurance
Adheres to stringent quality protocols aligned with USP, EP, BP, JP, and IP standards. A dedicated Quality Division ensures compliance through SOPs and STPs for raw materials and finished products.
9. Global Certifications
Holds multiple international quality certifications, including US-DMF, GMP, ISO 9001:2015, HACCP, KOSHER, HALAL, and FSSAI, reinforcing the company’s commitment to delivering globally compliant, high-quality products.
BUSINESS STRATEGIES
1. Expansion Through New Facility
A new manufacturing unit is being set up at Indrad, Mehsana to cater to the rising demand for Croscarmellose Sodium (CCS), Sodium Starch Glycolate (SSG), and Carboxymethyl Cellulose Calcium (Calcium CMC). The project will be funded through IPO proceeds to support scale-up and market capture.
2. Strengthening Global Presence
With exports to over 15 countries including the USA, Germany, UK, Japan, China, and Australia, the company aims to deepen international reach by enhancing distribution networks, expanding R&D, and entering new and emerging markets.
3. Product Innovation & Diversification
Focused on expanding the product portfolio through continuous R&D, enhancing existing offerings, and developing new specialty chemicals to address evolving market needs and drive future growth.
BUSINESS RISK FACTORS & CONCERNS
1. Geographic Concentration in Raw Material Procurement
A major portion of raw materials is procured from Gujarat, Maharashtra, and Delhi, with all imports sourced from China. In FY 2025, 94.34% of domestic purchases were from these three states, and 34.58% of total purchases were imported from China. Any disruption in supply or regulatory changes in these regions or China may adversely affect procurement and production timelines.
2. Regional Concentration in Domestic Sales
Domestic revenues are heavily reliant on Gujarat, Maharashtra, and West Bengal, accounting for 65.97% of total domestic sales in FY 2025. Revenue may be impacted by regional economic slowdowns, regulatory changes, or shifts in customer demand within these states.
3. Export Dependency on Select Countries
Key export markets include Egypt, USA, Russia, South Korea, UK, Japan, and Germany. Loss of business from any of these countries due to trade barriers, political changes, or demand fluctuations could negatively affect export revenues.
4. Exposure to End-Use Industry Risks
Revenue is indirectly tied to the performance of end-use sectors like pharmaceuticals, food & beverages, and cosmetics. Any downturn in these industries could reduce product demand and impact overall financial performance.
Patel Chem Specialities faces concentration risks across procurement, sales, and exports, with high dependency on specific geographies and industries. Changes in state or international regulations, geopolitical shifts, or disruptions in key sectors such as pharmaceuticals or cosmetics could significantly impact operations, revenues, and supply chains.
Patel Chem Specialities Limited Financial Information (Restated Consolidated)
Amount in (₹ in Lakh)
Period Ended
Mar 31, 2025
Mar 31, 2024
Mar 31, 2023
Reserve of Surplus
1,752.71
1,852.49
1,086.87
Total Assets
6,531.31
4,696.54
3,708.18
Total Borrowings
1,485.39
1,545.50
1,179.21
Fixed Assets
1,377.16
1,383.72
1,359.21
Cash
64.06
51.73
6.00
Net Borrowing
1,421.33
1,493.77
1,173.21
Revenue
10,555.18
8,271.61
6,974.75
EBITDA
1,573.03
1,202.18
582.64
PAT
1,056.52
765.62
288.61
EPS
6.1
4.5
1.7
Note 1:- RoE, ROCE & RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP. Note 2:- Pre EPS and Post EPS calculation in KPI is based (Profit/Loss for the Year) on 31st Mar, 2025 Data, given in RHP. Note 3:- RoNW calculation in KPI is based on 31st Mar, 2025 Data, given in RHP. Note 4:- Price to Book Value calculation in KPI is based on 31st Mar, 2025 Data, given in RHP.
Patel Chem Specialties Limited is a trusted leader in the manufacturing of high-quality pharmaceutical excipients - raw material for drug formulation. With decades of experience, they specialize in producing a wide range of excipients, including Sodium Carboxy Methyl Cellulose (Sodium CMC), Sodium Starch Glycolate (SSG), Croscarmellose sodium (CCS), Calcium CMC, Magnesium stearate andpregelatinised starch and also producing key API intermediate Sodium Monochloroacetate.
The leadership team, led by experienced promoters Bhupesh Patel and Anshu Patel, has been a driving force behind the Company’s success. Bhupesh Patel, the Managing Director, has more than 30 years of experience in the pharmaceuticals and nutraceutical industry. He has been instrumental in establishing the Company’s manufacturing plants and leads the product development & marketing strategies. Anshu Patel, the Whole-Time Director, holds a bachelor degree in Homoeopathic Medicine and Surgery and brings a decade of experience in the pharmaceuticals and nutraceutical industry. She oversees the Company’s strategic plan and its operations across various functions. Their industry experience and clear vision have helped the Company grow and stay competitive.
The Revenues from operations for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹10,555.18 Lakh, ₹ 8,271.61 Lakh and ₹ 6,974.75 Lakh. The EBITDA for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 1,573.02 Lakh, ₹ 1,202.18 Lakh and ₹ 582.64 Lakh. The Profit after Tax for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 1,056.52 Lakh, ₹ 765.62 Lakh and ₹ 288.61 Lakh respectively. This indicates a steady growth in financial performance.
The Company Key Performance Indicates the pre-issue EPS of ₹6.1and post-issue EPS of ₹ 4.25 for FY24.The pre-issue P/E ratio is 13.77x, while the post-issue P/E ratio is 19.77 against the Industry P/E ratio is 18x. The company's ROCE for FY24 is 36.26%, ROE for FY24 is 29.85% and RoNW is 24.32%. These metrics suggest that the IPO is fully priced.
The Grey Market Premium (GMP) of Patel Chem Specialities showing listing gains of 13.09 %.Given the company's financial performance and the valuation of the IPO, we recommend Risky Investors to Apply to the Patel Chem Specialities Limited IPO for Listing gain.
Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. 1.“Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.” 2. “Investment in securities market are subject to market risks. Read all the related documents carefully before investing.” 3. To read the Disclaimers, Disclosures, Investor Charter, Investor Complaints please visit our website abhayvarn.com
About the Author
CA Abhay Kumar (Also known as CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms.
